Get started
SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)

SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

0LC7 fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0LC7 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company